(Q40125495)

17 September 2017

title

Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins (English)

1 reference

17 September 2017

K G Wolter

1

1 reference

17 September 2017

M Verhaegen

2

1 reference

17 September 2017

Y Fernández

3

1 reference

17 September 2017

Z Nikolovska-Coleska

4

1 reference

17 September 2017

M Riblett

5

1 reference

17 September 2017

C Martin de la Vega

6

1 reference

17 September 2017

S Wang

7

1 reference

17 September 2017

M S Soengas

8

1 reference

17 September 2017

publication date

1 June 2007

1 reference

Cell Death & Differentiation

17 September 2017

published in

1 reference

17 September 2017

volume

14

1 reference

17 September 2017

issue

9

1 reference

17 September 2017

page(s)

1605-1616

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cdd.4402163

17 September 2017

exact match

0 references

cites work

Apoptosis and melanoma chemoresistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

Malignant melanoma: genetics and therapeutics in the genomic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

The development of proteasome inhibitors as anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

Ultraviolet radiation triggers apoptosis of fibroblasts and skin keratinocytes mainly via the BH3-only protein Noxa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

Pharmacological manipulation of Bcl-2 family members to control cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

Targeting Bcl-2 and Bcl-X with nonpeptidic small-molecule antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

Investigations on gossypol: past and present developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

21 January 2018

At the gates of death.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

Gossypol induces Bax/Bak-independent activation of apoptosis and cytochrome c release via a conformational change in Bcl-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

21 January 2018

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

7 January 2021

Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

7 January 2021

Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

7 January 2021

Stereo-specific cytotoxic effects of gossypol enantiomers and gossypolone in tumour cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

7 January 2021

Cytotoxicity of gossypol enantiomers and its quinone metabolite gossypolone in melanoma cell lines.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

7 January 2021

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

7 January 2021

Cell biology. Cellular demolition and the rules of engagement

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

7 January 2021

Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402163

7 January 2021

Identifiers

DOI

10.1038/SJ.CDD.4402163

1 reference

Dimensions Publication ID

17 September 2017

1009408982

0 references

1 reference